retatrutide clinical trial results weight loss 2024 2025 press release Results: 28.3% Data Retatrutide 2026: 28.3% Weight Loss

Individuals diagnosed with T2DM and at high risk for cardiovascular issues were studied to determine the effects of tirzepatide on their heart health

Tack J, Depoortere I, Bisschops R, Delporte C, Coulie B, Meulemans A, et al

Effects of curcumin-related compounds on GPR55 activation We compared the activation of GPR55 by curcumin with the minor curcuminoids demethoxycurcumin and bisdemethoxycurcumin, the reduced metabolite tetrahydrocurcumin, and the conjugate curcumin -d-glucuronide, which are present in vivo upon consumption of turmeric containing foods (Fig

When a patient may have less weight to lose in general, or they are reluctant to be on longer-term medication, phentermine can be a good option, says Vukasinov

I think it was out of Harvard

7583% achieved 15% 26% of participants on 12 mg achieved 30% weight reduction Cardiometabolic Parameters Improvements in blood pressure, HbA1c, fasting glucose, insulin, LDL-cholesterol 72% of patients with prediabetes achieved normoglycemia Safety Most common adverse events: gastrointestinal (nausea, diarrhea, constipation) , dose-dependent, predominantly mild to moderate Heart rate: slight increase up to week 24, then decrease No severe hypoglycemia, medullary carcinoma, or C-cell hyperplasia Conclusions Retatrutide induced significant, dose-dependent weight reduction of up to 24.2% over 48 weeks